PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29386360-0 2018 Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma. Tigecycline 28-39 B cell leukemia/lymphoma 2 Mus musculus 85-89 29386360-4 2018 BCL2 activation in mouse Emu-myc lymphomas antagonized tigecycline-induced cell death, which was specifically restored by combined treatment with the BCL2 inhibitor venetoclax. Tigecycline 55-66 B cell leukemia/lymphoma 2 Mus musculus 150-154 29386360-4 2018 BCL2 activation in mouse Emu-myc lymphomas antagonized tigecycline-induced cell death, which was specifically restored by combined treatment with the BCL2 inhibitor venetoclax. Tigecycline 55-66 B cell leukemia/lymphoma 2 Mus musculus 0-4